Celmatix has announced a commercial agreement with Oncotest-Teva, a subsidiary of Teva Pharmaceutical Industries, in Israel to bring the Fertilome test, the world’s first multigene panel test for a woman’s reproductive health and fertility, to the Israeli market. This partnership represents the first strategic international collaboration for Celmatix and will make the Fertilome genetic test widely available to women through their doctors in Israel. With the Fertilome test, Celmatix is ushering in a new era of personalized medicine in reproductive health. With this collaboration, the company is taking that movement global. A simple blood test ordered by a doctor, the Fertilome test can empower women to be more proactive about their family building by revealing whether they have genetic markers that have been associated with fertility-affecting conditions such as recurrent pregnancy loss, primary ovarian insufficiency, endometriosis, and polycystic ovary syndrome.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.